Acute effect of an alpha 1-adrenoceptor antagonist on urinary sodium excretion, plasma atrial natriuretic peptide, arginine vasopressin, and the renin-aldosterone system in healthy subjects

What Was Tested

The paper reports a study of Vasopressin and ANP (Atrial Natriuretic Peptide), published as a randomized controlled trial.

To elucidate the mechanism underlying the sodium retention caused by alpha 1-adrenoceptor blockade in man, a placebo-controlled, randomised, double-blind study has been made of the acute effects of bunazosin an alpha 1-antagonist, on urinary sodium excretion, atrial natriuretic peptide (ANP), arginine vasopressin (AVP), and the renin-aldosterone system in 7 healthy men.

Who Took Part

The study group was 7 men.

The age groups tagged for this paper are adults, men only.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

Because people in this Vasopressin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the men and researchers unaware of who received Vasopressin.

The comparison arm used a placebo, so changes seen with Vasopressin could be set against what happens without it.

What Was Measured

The subject headings attached to it are Adrenergic alpha-Antagonists, Arginine Vasopressin, Atrial Natriuretic Factor, Enalapril, Premedication, Quinazolines and Renin-Angiotensin System.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vasopressin and ANP (Atrial Natriuretic Peptide) in 7 men.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 1992 (European journal of clinical pharmacology), a journal based in Germany.

More context: the Vasopressin compound page and the ANP (Atrial Natriuretic Peptide) compound page, all human trials.